Crohns Disease Gut Microbiome: What Metagenomic Research Reveals
Research on the Crohns disease gut microbiome is helping scientists understand how bacterial composition influences the development and progression of this debilitating inflammatory condition. A study published in BMC Genomics analyzes the gut metagenome of patients with Crohns disease, elucidating how it influences the taxonomic and functional composition of intestinal microbiota.
Among the most common changes observed in the Crohns disease gut microbiome are a decrease in the diversity of beneficial microbes and an increased abundance of Escherichia coli and other inflammation associated species. These results can help better understand the causes and progression of the disease, as well as optimize treatment approaches.
What Is Crohns Disease?
Crohns disease is a severe inflammatory bowel disease that is widely prevalent in developed countries. Among its possible causal factors are genetic predisposition, environment, and patients’ lifestyle. The disease is associated with an abnormal reaction of the immune system to a person’s own gut microbes — a condition known as gut dysbiosis.
The Crohns disease gut microbiome has become a central focus of research because studying the role of bacteria in the pathological process offers a pathway toward more effective diagnostics and treatment.
What Is Metagenomic Analysis?
Among the most promising approaches to studying the Crohns disease gut microbiome is metagenomic analysis — the sequencing of total genetic material from a microbial community. A research team including scientists from ITMO University and specialists from the Federal Research and Clinical Center of Physical Chemical Medicine, in collaboration with clinicians from several medical centers, investigated the gut metagenome of patients with Crohns disease.
The researchers discovered that the composition of microbiota in patients with Crohns disease is significantly different compared to that of healthy subjects. As the fraction of normal microbes decreases, pathogenic species that are not prevalent in healthy people begin to dominate — a pattern consistently observed across the Crohns disease gut microbiome in multiple patient populations.
Escherichia Coli and the Crohns Disease Gut Microbiome
Although the type of dysbiosis varied from patient to patient, most manifested a several times increase in the abundance of Escherichia coli. The scientists set out to identify the specific genes that distinguish the subtypes of Escherichia coli inhabiting the gut of patients with Crohns disease from the common Escherichia coli found in healthy people.
The comparison conducted on the Russian population showed a lack of universal differences — an unexpected finding. These observations were confirmed during the analysis of publicly available datasets from healthy subjects and patients with Crohns disease from around the world.
Alexander Tyakht, a research associate at ITMO University, commented that the genetic content of Crohns disease associated Escherichia coli varies widely, despite the existing belief that only some specific varieties are involved. The results support the concept that Crohns disease is a syndrome — a disease in which similar manifestations across multiple cases are caused by different factors in each individual case.
Multiple Strains and the Crohns Disease Gut Microbiome
The research indicated that several strains of Escherichia coli can coexist in a human gut. Since strains with different genomes can play significantly different ecological roles, the same treatment schemes can have very different effects on different strains.
This discovery offers an opportunity to improve the balance of the Crohns disease gut microbiome in patients, while personalized analysis of bacterial genotype offers an opportunity to select the most effective medications, probiotics, and even fecal mass transplantation donors for each individual patient.
What These Findings Mean for Treatment
These findings also resonate with earlier research involving genome analysis of isolated E. coli strains. The results shed light on how microbiota changes in patients with Crohns disease and which species and strains of bacteria participate in its development — ultimately helping to better understand the onset and progression of the disease and optimize treatment methods.
Understanding how research like this translates into new therapies requires understanding the clinical trial process. Our introduction to clinical trials explains how discoveries move from metagenomic research into Phase I through Phase IV studies and ultimately into patient care.
For those interested in how personalized data analysis is reshaping medicine more broadly, our article on personalized medicine drug discovery explores how genomic, tissue, and biomarker data are being combined to develop more targeted therapies.
According to the Crohns and Colitis Foundation, approximately 780,000 Americans are currently living with Crohns disease — making advances in understanding the Crohns disease gut microbiome a critical priority for gastroenterology research.
Source: dddmag.com